Companies news • Communication - Press • Members
Genoskin Raises Series A to Advance Human-Based Drug Development
Genoskin secures Series A funding to fuel global growth and advance ethical alternatives to animal testing.
Genoskin, a leader in ex vivo human skin platforms, has raised Series A funding to accelerate global expansion and strengthen its scientific leadership. The investment will enable Genoskin to scale operations, expand production capacity, and continue developing ethical, human-relevant alternatives to animal testing.
The company is opening new production facilities in Salem, MA (2026) and Toulouse, France (2027), which will double its capacity for human skin models and introduce U.S. production of fresh human primary mast cells for next-day delivery. Increased automation and process optimization will support this scale-up while maintaining the highest standards of quality and reliability.
Genoskin’s human skin platforms provide more predictive insights into drug and medical device safety and efficacy than traditional animal models. Its bio-stabilized, immunocompetent skin samples remain viable for up to seven days, giving biotech, pharma, and cosmetics companies sustainable access to high-quality, human-relevant data.
“Our human-based platforms provide more predictive insights than animal models,” said Pascal Descargues, Ph.D., CEO of Genoskin. “This funding allows us to scale globally and advance our mission to support safer, more effective therapies.”
In addition to expanding infrastructure, Genoskin is enhancing its scientific leadership by developing next-generation biosimulation platforms and immune models. These innovations are designed to accelerate therapeutic development, reduce reliance on animal testing, and support the industry’s shift toward ethical, human-relevant research.
